S
AVBP icon

SignatureFD’s ArriVent BioPharma AVBP Stock Holding History

SignatureFD’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.49K Hold
368
– – ﹤0.01% 2575
2025
Q4 		$7.4K Hold
368
– – ﹤0.01% 2558
2025
Q3 		$6.79K Buy
368
+350
+1,944% +$6.88K ﹤0.01% 2542
2025
Q2 		$392 Buy
+18
New +$374 ﹤0.01% 3139

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SignatureFD's AVBP Position: Q1 2026 in Review

SignatureFD held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 368 shares worth $8.49K. The position accounts for ﹤0.01% of the portfolio, ranked #2575.

SignatureFD first reported a position in AVBP in Q2 2025 and has held it in 4 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • SignatureFD held 368 shares of ArriVent BioPharma worth $8.49K as of Q1 2026.
  • SignatureFD left its ArriVent BioPharma share count unchanged in Q1 2026.
  • ArriVent BioPharma made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #2575 holding.
  • SignatureFD first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 4 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.